JAMA Dermatol:大疱性类天疱疮黏膜受累的患病率评估

2019-04-27 陈俭波 报道 张桂英 审校,中南大学湘雅二医院皮肤科 医学参考报皮肤病与性病学频道

大疱性类天疱疮黏膜受累的患病率评估

大多数大疱性类天疱疮( BP )患者主要表现为紧张的水疱和红斑,多见于四肢屈侧和腹部,并常伴有荨麻疹样斑块。20%的BP患者有非典型的表现,包括痒疹样、荨麻疹样、湿疹样和汗疱疹样。根据Vaillant等人的BP临床诊断标准,此标准对BP的临床诊断有95 %的阳性预测率,认为粘膜受累是BP的不典型特征。BP中的典型粘膜病变局限于口腔粘膜,发病率可高达20%,但在不同的研究组中,BP患者口腔粘膜受累的发生率差异很大,而缺乏其他粘膜的受累情况的研究,并且这些数据主要是来源于个案病例报道,据报道,新加坡BP患者口腔年率受累的发生率低至5.7 %,而瑞士和法国北部的发生率率则高达为14.5 %和18.6 %。目前,BP患者非口腔粘膜受累的情况尚缺乏队列研究或大病例系列研究报告,并且对可能会影响BP患者的确切粘膜结构以及有粘膜受累的BP患者的特征的了解非常有限。

为了评估BP患者粘膜受累的患病率和分布,作者进行了一项回顾性队列研究,选取了2000年1月1日至2017年12月31日在以色列北部的自身免疫性大疱性疾病三级护理转诊中心免疫病理学确诊为BP的328名患者。在临床和免疫学特征、实验室分析和治疗方面,粘膜受累患者与其余BP患者进行了比较。研究队列包括139名(42.4% )男性和189名( 57.6% )女性患者,平均年龄为78.0±11.8岁。56名患者( 17.1%)出现粘膜病变。口腔粘膜是受累最多(n = 44; 13.7%),其次是喉部黏膜(n =16; 4.9%)和生殖器黏膜(n = 10; 3.0%)。口腔病变患者中,口腔受累最严重的部位是颊粘膜(n =25; 55.6%)和软腭(n = 24; 53.3%)。与其他BP患者相比,粘膜受累的患者较年轻(71.8±14.4岁vs 79.3±10.8岁;P < 0.001),常表现为为广泛性的( 55.4 % vs 39.7 %;P = 0.002),外周嗜酸性粒细胞减少( 17.8 % vs 41.9 %;P < 0.001),皮质类固醇治疗剂量更大(泼尼松> 1mg/kg: 67.9% vs51.8 %;P =0.03)。

这项研究表明,口腔粘膜是受影响最频繁的粘膜表面,特别是其非角化部位,而角化粘膜部位如牙龈和舌背的受累频率较低,大部分患者中有一个口腔部位的单独受累,说明BP的口腔病变是一个惰性的过程。喉粘膜受累比以前报道的更为严重,这可能是因为既往研究在有其他黏膜受累而没有喉部症状时,未进一步行间接纤维喉镜检查。粘膜受累的患者有更严重和更广泛的皮损,需要更积极的治疗来达到临床缓解。粘膜受累的患者常出现头颈部皮肤皮损,这种表现被认为是一种不典型的临床特征,有助于BP与其他表皮下大疱病的鉴别诊断。此外,粘膜受累患者外周嗜酸性粒细胞减少;考虑循环或浸润的嗜酸性粒细胞是否对皮肤粘膜BP的发展起到保护作用。因此临床医生应该重视BP中粘膜受累的情况,以协助临床病情评估及治疗。

原始出处:

Khalaf Kridin,  Reuven Bergman. Assessment of the Prevalence of Mucosal Involvement in Bullous Pemphigoid. JAMA Dermatol. 2019;155(2):166-171. doi:10.1001/jamadermatol.2018.5049.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=945597, encodeId=ba7994559eda, content=学习了,非常感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc915465725, createdName=ms2000001920907590, createdTime=Fri Mar 05 06:07:39 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775157, encodeId=2a7e1e751574f, content=<a href='/topic/show?id=c56f43e89eb' target=_blank style='color:#2F92EE;'>#大疱性类天疱疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43789, encryptionId=c56f43e89eb, topicName=大疱性类天疱疮)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc0e38759441, createdName=freve, createdTime=Thu Feb 13 01:13:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250618, encodeId=5cb11250618f5, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Mon Apr 29 01:13:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520029, encodeId=216915200291f, content=<a href='/topic/show?id=6ab11032506f' target=_blank style='color:#2F92EE;'>#黏膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103250, encryptionId=6ab11032506f, topicName=黏膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=057f11309297, createdName=snowpeakxu, createdTime=Mon Apr 29 01:13:00 CST 2019, time=2019-04-29, status=1, ipAttribution=)]
    2021-03-05 ms2000001920907590

    学习了,非常感谢

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=945597, encodeId=ba7994559eda, content=学习了,非常感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc915465725, createdName=ms2000001920907590, createdTime=Fri Mar 05 06:07:39 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775157, encodeId=2a7e1e751574f, content=<a href='/topic/show?id=c56f43e89eb' target=_blank style='color:#2F92EE;'>#大疱性类天疱疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43789, encryptionId=c56f43e89eb, topicName=大疱性类天疱疮)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc0e38759441, createdName=freve, createdTime=Thu Feb 13 01:13:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250618, encodeId=5cb11250618f5, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Mon Apr 29 01:13:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520029, encodeId=216915200291f, content=<a href='/topic/show?id=6ab11032506f' target=_blank style='color:#2F92EE;'>#黏膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103250, encryptionId=6ab11032506f, topicName=黏膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=057f11309297, createdName=snowpeakxu, createdTime=Mon Apr 29 01:13:00 CST 2019, time=2019-04-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=945597, encodeId=ba7994559eda, content=学习了,非常感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc915465725, createdName=ms2000001920907590, createdTime=Fri Mar 05 06:07:39 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775157, encodeId=2a7e1e751574f, content=<a href='/topic/show?id=c56f43e89eb' target=_blank style='color:#2F92EE;'>#大疱性类天疱疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43789, encryptionId=c56f43e89eb, topicName=大疱性类天疱疮)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc0e38759441, createdName=freve, createdTime=Thu Feb 13 01:13:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250618, encodeId=5cb11250618f5, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Mon Apr 29 01:13:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520029, encodeId=216915200291f, content=<a href='/topic/show?id=6ab11032506f' target=_blank style='color:#2F92EE;'>#黏膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103250, encryptionId=6ab11032506f, topicName=黏膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=057f11309297, createdName=snowpeakxu, createdTime=Mon Apr 29 01:13:00 CST 2019, time=2019-04-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=945597, encodeId=ba7994559eda, content=学习了,非常感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc915465725, createdName=ms2000001920907590, createdTime=Fri Mar 05 06:07:39 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775157, encodeId=2a7e1e751574f, content=<a href='/topic/show?id=c56f43e89eb' target=_blank style='color:#2F92EE;'>#大疱性类天疱疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43789, encryptionId=c56f43e89eb, topicName=大疱性类天疱疮)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc0e38759441, createdName=freve, createdTime=Thu Feb 13 01:13:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250618, encodeId=5cb11250618f5, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Mon Apr 29 01:13:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520029, encodeId=216915200291f, content=<a href='/topic/show?id=6ab11032506f' target=_blank style='color:#2F92EE;'>#黏膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103250, encryptionId=6ab11032506f, topicName=黏膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=057f11309297, createdName=snowpeakxu, createdTime=Mon Apr 29 01:13:00 CST 2019, time=2019-04-29, status=1, ipAttribution=)]
    2019-04-29 snowpeakxu

相关资讯

NEJM:病例报道——大庖性类天疱疮

女性患者,73岁,因严重的皮肤瘙痒及前臂、背部下方以及腿部的张力性水疱而就诊,时间长达2周。

Health Technol Assess:大疱性类天疱疮:多西环素PK泼尼松龙

大疱性类天疱疮(BP)是老年患者一种自身免疫性起泡皮肤病,并增加发病率和死亡率。2017年,发表在《Health Technol Assess.》的一项多中心、双臂、平行组、随机对照试验调查了口服多西环素及口服泼尼松龙用于治疗BP的安全性、有效性及成本效果。

2016大疱性类天疱疮诊断和治疗的专家建议发布

大疱性类天疱疮(bullous pemphigoid,BP)是自身免疫性大疱性疾病,老年人多见,偶见于儿童和青少年。临床表现为紧张性水疱和大疱,尼氏征阴性,有不同程度的瘙痒,多数不伴黏膜损害。BP患者血清中产生针对皮肤基底膜带的循环自身抗体,包括抗表皮基底膜抗原230 000(BP230,BPAGl)、180 000(BPl80,BPAG2)两种主要自身抗体,简称抗BP230和抗BPl80。抗BP

Lancet:多西环素与泼尼松龙治疗大疱性类天疱疮哪个更优?

大疱性类天疱疮是一种起泡性皮肤病,能够增加患者的死亡率。近期,一项发表在权威杂志LANCET上研究评估了开始使用多西环素治疗的策略是否能够提供可接受的短期水泡控制作用,同时评估与口服皮质类固醇相比,能否提供长期安全优点的治疗。此项研究为多中心,平行组随机对照试验,招募了成年大疱性类天疱疮患者(在两个或更多点出现三个或更多的水泡,且有线性基底膜IgG或C3)。参与者随机分配使用多西环素(200mg

JAMA Dermatol:大疱性类天疱疮的血清抗体研究

大疱性类天疱疮(BP)是最常见的自身免疫性大疱性疾病。既往有报道称,22%到100%的BP血清样品中,IgE抗体能对抗跨膜蛋白BP抗原2 (BP180, XVII型胶原),多种实验模型也提出了抗BP180 IgE致病的相关性,使用奥马珠单抗治疗BP患者也取得了成功。 研究目的是,确定BP患者中抗BP180 IgE率,评估抗BP180 IgE与诊断BP的相关性,抗BP180 IgE与疾病活动和